Filing Flows › Niagen Bioscience (NAGE) › Q3 2026
Niagen Bioscience (NAGE) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Niagen Bioscience (NAGE) reported revenue of $27.2M for the third quarter 2026 (Q3 2026), -20% from a year earlier and -9% from the quarter before. Operating margin was -5.8%, net loss $1.2M (4.3% of revenue).
Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%, net loss $1.2M, operating cash flow $2.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $27.2M | -9% | -20% |
| Operating profit | −$1.6M | -327% | -137% |
| Net earnings | −$1.2M | -222% | -126% |
| Operating cash flow | $2.6M | -5% | -29% |
What changed
Revenue was $27.2M in Q3 2026, down 20% year over year and down 9% from the previous quarter. Consumer Products segment was the largest line at 86% of revenue. Ingredients segment lost $3.4M year over year (down 47%), 50% of the total change.
Gross margin was 62.9%, down 1.6 points from Q3 2025. Operating costs exceeded revenue by $1.6M, an operating margin of -5.8%. Operating expenses grew 6% against a revenue fall of 20%. The fastest-growing cost line was General & admin (+15%). The quarter ended with a net loss of $1.2M, after a profit of $1.0M the previous quarter. Non-operating items added $414K, -35% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $2.6M (down 29% year over year). Non-cash charges added back $290K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items added $2.0M.
Questions
What was Niagen Bioscience's revenue in the third quarter 2026?
Niagen Bioscience (NAGE) reported revenue of $27.2M for the third quarter 2026 (Q3 2026), -20% from a year earlier and -9% from the quarter before.
Was Niagen Bioscience profitable in the third quarter 2026?
Operating loss was $1.6M (-5.8% of revenue) and net loss $1.2M.
Source: Niagen Bioscience 10-Q on SEC EDGAR.